Eyetech's Strong IPO Performance Provides Momentum To Filed Bids
Any pupil of biotech will tell you: One eyebrow-raising initial public offering does not an IPO wave make. Still, observers held hopes that if Eyetech Pharmaceuticals Inc. came through with a solid pricing and decent after-market performance, more of the pending IPOs might follow suit.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter